Health 2.0 Europe 2011

27 - 28 October 2011, Berlin, Germany.
Following the success of the first edition in Paris in April 2010, the 2nd annual Health 2.0 Europe in Berlin has been announced. The 2010 event gathered over 500 delegates in its first year and showcased the best of Europe's Health 2.0 offerings with some American input too. Co-hosted with K.I.T. Group, the 2nd edition will reconvene all the leaders and stakeholders in web 2.0 health: IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical devices and pharmaceutical companies, telecom groups, VC and financiers, policy makers, academics and more...

2011 Program Highlights
Health 2.0 Europe integrates the best of European web/mobile based technologies, and compares, contrasts and contextualizes them with leading examples of Health 2.0 from around the world. Health 2.0 Europe will be seeing what works in the context of Europe's evolving healthcare systems, and what the "boundary-less" online world means for consumers and physicians working in distinct healthcare systems - all in the lauded format of "rapid-fire" technology demos, provocative keynotes, and interactive discussions. 2011 themes will include:

  • Patient and physician social networks
  • Search & content
  • Communities and data production
  • Consumer and provider tools
  • Health promotion and wellness 2.0
  • Behavior change tools
  • Privacy, data, trust
  • Data utility layer & tools
  • System integration
  • Health 2.0 financing
  • Mobile devices and smart phones

There'll also be a presentation of the latest thinking about Health 2.0 in the European context, special videos, and an unconference session.

A signature of the Health 2.0 conferences, Launch!, will be back by popular demand. Come witness live demos of debuting technologies that will shape the future of healthcare.

Make it your event. Get involved now!
To submit a topic, a speaker, or a start up for the Launch! session, or to inquire about becoming a partner of the event, please contact:

Pascal Lardier, Director, International conferences
This email address is being protected from spambots. You need JavaScript enabled to view it.

Historical Venue
After the Cité Internationale in April 2010, the 2011 event is taking us to yet another historical landmark: the Langenbeck-Virchow building of the Charité Hospital and University of Medicine.

It was built in 1914-15 to be the seat of the German Surgical Society and the Berlin Medical Association. From 1950 to 1976, the Parliament of East Germany was constituted in its auditorium and started convening in the Great Hall. After the collapse of Berlin Wall in 1989 and a long legal conflict, the German Surgical Society and the Berlin Medical Association returned to their home.

For further information and registration, please visit:
http://www.health2con.com/europe/

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...